Cmic Holdings Co
Cmic Holdings Co., a prominent player in the pharmaceutical and biotechnology industry, is headquartered in Japan (JP) and operates extensively across Asia and beyond. Founded in 2006, the company has established itself as a leader in contract research and manufacturing services, catering to a diverse clientele in the life sciences sector. Cmic Holdings is renowned for its comprehensive range of services, including drug development, clinical trial management, and regulatory affairs. What sets them apart is their commitment to innovation and quality, ensuring that clients receive tailored solutions that meet stringent industry standards. With a strong market position, Cmic Holdings has achieved significant milestones, including strategic partnerships and expansions that enhance its service offerings.
DitchCarbon Score
How does Cmic Holdings Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cmic Holdings Co's score of 32 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cmic Holdings Co's reported carbon emissions
In 2023, Cmic Holdings Co, headquartered in Japan, reported total carbon emissions of approximately 8,000,000 kg CO2e, comprising 1,000,000 kg CO2e from Scope 1 and 7,000,000 kg CO2e from Scope 2. This marks a significant reduction from previous years, with emissions of about 44,000,000 kg CO2e in 2022, 42,000,000 kg CO2e in 2021, and 43,000,000 kg CO2e in 2020. Cmic Holdings has demonstrated a commitment to reducing its carbon footprint, although it has not set a net-zero target. The company is currently classified as "Committed" to near-term reduction targets, indicating a proactive approach to climate action within the pharmaceuticals, biotechnology, and life sciences sector. The emissions data reflects a trend of decreasing emissions over the years, showcasing the company's efforts to enhance sustainability practices. Cmic Holdings continues to focus on reducing its Scope 1 and Scope 2 emissions, aligning with industry standards for climate responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cmic Holdings Co is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
